Access Biotechnology

Access Biotechnology is the life science investment arm of Access Industries. They invest in transformative therapies for conditions with high unmet needs and that have the potential to meaningfully impact human health. They invest in both private and public biopharma companies across therapeutic areas, modalities, and development stages – from discovery-stage technology platforms to late-stage clinical programs.

The company is based in New York.

Access Biotechnology, established in 1986 and headquartered in New York, New York, United States, North America., specializes in Early Stage Venture, Seed, Late Stage Venture investments across Biotechnology, Health Care, Pharmaceutical, Biopharma, Financial Services, Finance, Asset Management, Insurance, Advice, Venture Capital. The organization boasts a portfolio of 33 investments, with an average round size of $113.0M and 12 successful exits. Their recent investments include Day One Biopharmaceuticals, Wellington Management, Frazier Healthcare Partners, Deerfield, Fairmount Funds Management. The highest investment round they participated in was $426.6B. Among their most notable exits are Day One Biopharmaceuticals and Wellington Management. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.